#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Atherosclerosis is a common pathology that affects large and medium arteries leading to a variety of cardiovascular events that can also be fatal , therefore representing a serious public health problem .
2-1	16-31	Atherosclerosis	abstract	new	coref	2-3[3_0]
2-2	32-34	is	_	_	_	_
2-3	35-36	a	abstract[3]	giv[3]	coref	3-1[0_3]
2-4	37-43	common	abstract[3]	giv[3]	_	_
2-5	44-53	pathology	abstract[3]	giv[3]	_	_
2-6	54-58	that	abstract[3]	giv[3]	_	_
2-7	59-66	affects	abstract[3]	giv[3]	_	_
2-8	67-72	large	abstract[3]|object[4]	giv[3]|new[4]	_	_
2-9	73-76	and	abstract[3]|object[4]	giv[3]|new[4]	_	_
2-10	77-83	medium	abstract[3]|object[4]	giv[3]|new[4]	_	_
2-11	84-92	arteries	abstract[3]|object[4]	giv[3]|new[4]	_	_
2-12	93-100	leading	abstract[3]|object[4]	giv[3]|new[4]	_	_
2-13	101-103	to	abstract[3]|object[4]	giv[3]|new[4]	_	_
2-14	104-105	a	abstract[3]|object[4]|abstract[5]	giv[3]|new[4]|new[5]	_	_
2-15	106-113	variety	abstract[3]|object[4]|abstract[5]	giv[3]|new[4]|new[5]	_	_
2-16	114-116	of	abstract[3]|object[4]|abstract[5]	giv[3]|new[4]|new[5]	_	_
2-17	117-131	cardiovascular	abstract[3]|object[4]|abstract[5]|event[6]	giv[3]|new[4]|new[5]|new[6]	coref	5-16[28_6]
2-18	132-138	events	abstract[3]|object[4]|abstract[5]|event[6]	giv[3]|new[4]|new[5]|new[6]	_	_
2-19	139-143	that	abstract[3]|object[4]|abstract[5]|event[6]	giv[3]|new[4]|new[5]|new[6]	_	_
2-20	144-147	can	abstract[3]|object[4]|abstract[5]|event[6]	giv[3]|new[4]|new[5]|new[6]	_	_
2-21	148-152	also	abstract[3]|object[4]|abstract[5]|event[6]	giv[3]|new[4]|new[5]|new[6]	_	_
2-22	153-155	be	abstract[3]|object[4]|abstract[5]|event[6]	giv[3]|new[4]|new[5]|new[6]	_	_
2-23	156-161	fatal	abstract[3]|object[4]|abstract[5]|event[6]	giv[3]|new[4]|new[5]|new[6]	_	_
2-24	162-163	,	_	_	_	_
2-25	164-173	therefore	_	_	_	_
2-26	174-186	representing	_	_	_	_
2-27	187-188	a	abstract[8]	new[8]	_	_
2-28	189-196	serious	abstract[8]	new[8]	_	_
2-29	197-203	public	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-30	204-210	health	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-31	211-218	problem	abstract[8]	new[8]	_	_
2-32	219-220	.	_	_	_	_

#Text=Atherosclerosis is characterized by progressive lipid deposition in the arterial wall , plaque induction and possible further progression to the state of so-called unstable plaque .
3-1	221-236	Atherosclerosis	abstract	giv	coref	7-13
3-2	237-239	is	_	_	_	_
3-3	240-253	characterized	_	_	_	_
3-4	254-256	by	_	_	_	_
3-5	257-268	progressive	event[10]	new[10]	_	_
3-6	269-274	lipid	event[10]	new[10]	_	_
3-7	275-285	deposition	event[10]	new[10]	_	_
3-8	286-288	in	event[10]	new[10]	_	_
3-9	289-292	the	event[10]|object[11]	new[10]|new[11]	_	_
3-10	293-301	arterial	event[10]|object[11]	new[10]|new[11]	_	_
3-11	302-306	wall	event[10]|object[11]	new[10]|new[11]	_	_
3-12	307-308	,	_	_	_	_
3-13	309-315	plaque	object|event[13]	new|new[13]	coref	3-23[16_0]
3-14	316-325	induction	event[13]	new[13]	_	_
3-15	326-329	and	_	_	_	_
3-16	330-338	possible	event[14]	new[14]	coref	18-14[0_14]
3-17	339-346	further	event[14]	new[14]	_	_
3-18	347-358	progression	event[14]	new[14]	_	_
3-19	359-361	to	event[14]	new[14]	_	_
3-20	362-365	the	event[14]|abstract[15]	new[14]|new[15]	_	_
3-21	366-371	state	event[14]|abstract[15]	new[14]|new[15]	_	_
3-22	372-374	of	event[14]|abstract[15]	new[14]|new[15]	_	_
3-23	375-384	so-called	event[14]|abstract[15]|object[16]	new[14]|new[15]|giv[16]	coref	4-10[19_16]
3-24	385-393	unstable	event[14]|abstract[15]|object[16]	new[14]|new[15]|giv[16]	_	_
3-25	394-400	plaque	event[14]|abstract[15]|object[16]	new[14]|new[15]|giv[16]	_	_
3-26	401-402	.	_	_	_	_

#Text=Advanced plaques usually acquire a fibrous cap that separates the plaque from the surrounding milieu and plays a stabilizing role .
4-1	403-411	Advanced	object[17]	new[17]	coref	5-3[0_17]
4-2	412-419	plaques	object[17]	new[17]	_	_
4-3	420-427	usually	_	_	_	_
4-4	428-435	acquire	_	_	_	_
4-5	436-437	a	object[18]	new[18]	_	_
4-6	438-445	fibrous	object[18]	new[18]	_	_
4-7	446-449	cap	object[18]	new[18]	_	_
4-8	450-454	that	object[18]	new[18]	_	_
4-9	455-464	separates	object[18]	new[18]	_	_
4-10	465-468	the	object[18]|object[19]	new[18]|giv[19]	coref	6-19[0_19]
4-11	469-475	plaque	object[18]|object[19]	new[18]|giv[19]	_	_
4-12	476-480	from	object[18]	new[18]	_	_
4-13	481-484	the	object[18]|place[20]	new[18]|new[20]	_	_
4-14	485-496	surrounding	object[18]|place[20]	new[18]|new[20]	_	_
4-15	497-503	milieu	object[18]|place[20]	new[18]|new[20]	_	_
4-16	504-507	and	object[18]	new[18]	_	_
4-17	508-513	plays	object[18]	new[18]	_	_
4-18	514-515	a	object[18]|abstract[21]	new[18]|new[21]	coref	9-7[52_21]
4-19	516-527	stabilizing	object[18]|abstract[21]	new[18]|new[21]	_	_
4-20	528-532	role	object[18]|abstract[21]	new[18]|new[21]	_	_
4-21	533-534	.	_	_	_	_

#Text=Destabilization of plaques leads to their rupture with subsequent thrombus formation that can lead to dangerous events such as acute coronary syndrome ( ACS ) and stroke .
5-1	535-550	Destabilization	abstract[22]	new[22]	_	_
5-2	551-553	of	abstract[22]	new[22]	_	_
5-3	554-561	plaques	abstract[22]|object	new[22]|giv	ana	5-6
5-4	562-567	leads	_	_	_	_
5-5	568-570	to	_	_	_	_
5-6	571-576	their	object|event[25]	giv|new[25]	coref	6-1[33_0]
5-7	577-584	rupture	event[25]	new[25]	_	_
5-8	585-589	with	event[25]	new[25]	_	_
5-9	590-600	subsequent	event[25]|event[27]	new[25]|new[27]	coref	6-8[34_27]
5-10	601-609	thrombus	event[25]|abstract|event[27]	new[25]|new|new[27]	_	_
5-11	610-619	formation	event[25]|event[27]	new[25]|new[27]	_	_
5-12	620-624	that	event[25]|event[27]	new[25]|new[27]	_	_
5-13	625-628	can	event[25]|event[27]	new[25]|new[27]	_	_
5-14	629-633	lead	event[25]|event[27]	new[25]|new[27]	_	_
5-15	634-636	to	event[25]|event[27]	new[25]|new[27]	_	_
5-16	637-646	dangerous	event[25]|event[27]|event[28]	new[25]|new[27]|giv[28]	_	_
5-17	647-653	events	event[25]|event[27]|event[28]	new[25]|new[27]|giv[28]	_	_
5-18	654-658	such	event[25]|event[27]|event[28]	new[25]|new[27]|giv[28]	_	_
5-19	659-661	as	event[25]|event[27]|event[28]	new[25]|new[27]|giv[28]	_	_
5-20	662-667	acute	event[25]|event[27]|event[28]|abstract[30]	new[25]|new[27]|giv[28]|new[30]	appos	5-24[0_30]
5-21	668-676	coronary	event[25]|event[27]|event[28]|person|abstract[30]	new[25]|new[27]|giv[28]|new|new[30]	_	_
5-22	677-685	syndrome	event[25]|event[27]|event[28]|abstract[30]	new[25]|new[27]|giv[28]|new[30]	_	_
5-23	686-687	(	_	_	_	_
5-24	688-691	ACS	abstract	giv	_	_
5-25	692-693	)	_	_	_	_
5-26	694-697	and	_	_	_	_
5-27	698-704	stroke	event	new	_	_
5-28	705-706	.	_	_	_	_

#Text=Advanced complicated plaques are also characterized by the formation of the necrotic core , pathological vascular remodeling , plaque neovascularization and calcification .
6-1	707-715	Advanced	object[33]	giv[33]	coref	7-25[45_33]
6-2	716-727	complicated	object[33]	giv[33]	_	_
6-3	728-735	plaques	object[33]	giv[33]	_	_
6-4	736-739	are	_	_	_	_
6-5	740-744	also	_	_	_	_
6-6	745-758	characterized	_	_	_	_
6-7	759-761	by	_	_	_	_
6-8	762-765	the	event[34]	giv[34]	_	_
6-9	766-775	formation	event[34]	giv[34]	_	_
6-10	776-778	of	event[34]	giv[34]	_	_
6-11	779-782	the	event[34]|object[35]	giv[34]|new[35]	_	_
6-12	783-791	necrotic	event[34]|object[35]	giv[34]|new[35]	_	_
6-13	792-796	core	event[34]|object[35]	giv[34]|new[35]	_	_
6-14	797-798	,	event[34]	giv[34]	_	_
6-15	799-811	pathological	event[34]|event[36]	giv[34]|new[36]	_	_
6-16	812-820	vascular	event[34]|event[36]	giv[34]|new[36]	_	_
6-17	821-831	remodeling	event[34]|event[36]	giv[34]|new[36]	_	_
6-18	832-833	,	event[34]	giv[34]	_	_
6-19	834-840	plaque	event[34]|object|abstract[38]	giv[34]|giv|new[38]	coref	16-14[121_0]
6-20	841-859	neovascularization	event[34]|abstract[38]	giv[34]|new[38]	_	_
6-21	860-863	and	event[34]	giv[34]	_	_
6-22	864-877	calcification	event[34]|abstract	giv[34]|new	_	_
6-23	878-879	.	_	_	_	_

#Text=Elevated low-density lipoprotein ( LDL ) is known to be associated with atherosclerosis and is identified as the major source of lipids accumulating in atherosclerotic plaques .
7-1	880-888	Elevated	substance[40]	new[40]	_	_
7-2	889-900	low-density	substance[40]	new[40]	_	_
7-3	901-912	lipoprotein	substance[40]	new[40]	_	_
7-4	913-914	(	_	_	_	_
7-5	915-918	LDL	abstract	new	coref	8-1[46_0]
7-6	919-920	)	_	_	_	_
7-7	921-923	is	_	_	_	_
7-8	924-929	known	_	_	_	_
7-9	930-932	to	_	_	_	_
7-10	933-935	be	_	_	_	_
7-11	936-946	associated	_	_	_	_
7-12	947-951	with	_	_	_	_
7-13	952-967	atherosclerosis	abstract	giv	coref	9-11
7-14	968-971	and	_	_	_	_
7-15	972-974	is	_	_	_	_
7-16	975-985	identified	_	_	_	_
7-17	986-988	as	_	_	_	_
7-18	989-992	the	abstract[43]	new[43]	_	_
7-19	993-998	major	abstract[43]	new[43]	_	_
7-20	999-1005	source	abstract[43]	new[43]	_	_
7-21	1006-1008	of	abstract[43]	new[43]	_	_
7-22	1009-1015	lipids	abstract[43]|substance[44]	new[43]|new[44]	_	_
7-23	1016-1028	accumulating	abstract[43]|substance[44]	new[43]|new[44]	_	_
7-24	1029-1031	in	abstract[43]|substance[44]	new[43]|new[44]	_	_
7-25	1032-1047	atherosclerotic	abstract[43]|substance[44]|object[45]	new[43]|new[44]|giv[45]	_	_
7-26	1048-1055	plaques	abstract[43]|substance[44]|object[45]	new[43]|new[44]|giv[45]	_	_
7-27	1056-1057	.	_	_	_	_

#Text=Circulating modified LDL has increased atherogenicity in comparison to native LDL .
8-1	1058-1069	Circulating	abstract[46]	giv[46]	coref	8-10[49_46]
8-2	1070-1078	modified	abstract[46]	giv[46]	_	_
8-3	1079-1082	LDL	abstract[46]	giv[46]	_	_
8-4	1083-1086	has	_	_	_	_
8-5	1087-1096	increased	abstract[47]	new[47]	_	_
8-6	1097-1111	atherogenicity	abstract[47]	new[47]	_	_
8-7	1112-1114	in	_	_	_	_
8-8	1115-1125	comparison	abstract[48]	new[48]	_	_
8-9	1126-1128	to	abstract[48]	new[48]	_	_
8-10	1129-1135	native	abstract[48]|abstract[49]	new[48]|giv[49]	coref	9-4[0_49]
8-11	1136-1139	LDL	abstract[48]|abstract[49]	new[48]|giv[49]	_	_
8-12	1140-1141	.	_	_	_	_

#Text=Chemical modification of LDL likely plays a prominent role in atherosclerosis development .
9-1	1142-1150	Chemical	event[50]	new[50]	_	_
9-2	1151-1163	modification	event[50]	new[50]	_	_
9-3	1164-1166	of	event[50]	new[50]	_	_
9-4	1167-1170	LDL	event[50]|abstract	new[50]|giv	coref	10-2[55_0]
9-5	1171-1177	likely	_	_	_	_
9-6	1178-1183	plays	_	_	_	_
9-7	1184-1185	a	abstract[52]	giv[52]	_	_
9-8	1186-1195	prominent	abstract[52]	giv[52]	_	_
9-9	1196-1200	role	abstract[52]	giv[52]	_	_
9-10	1201-1203	in	abstract[52]	giv[52]	_	_
9-11	1204-1219	atherosclerosis	abstract[52]|abstract|event[54]	giv[52]|giv|new[54]	coref	13-22
9-12	1220-1231	development	abstract[52]|event[54]	giv[52]|new[54]	_	_
9-13	1232-1233	.	_	_	_	_

#Text=Besides elevated LDL , chronic inflammation is now considered as another crucial pro-atherogenic mechanism that can even precede lipid entry into the arterial intima .
10-1	1234-1241	Besides	_	_	_	_
10-2	1242-1250	elevated	abstract[55]	giv[55]	_	_
10-3	1251-1254	LDL	abstract[55]	giv[55]	_	_
10-4	1255-1256	,	_	_	_	_
10-5	1257-1264	chronic	event[56]	new[56]	coref	13-16[0_56]
10-6	1265-1277	inflammation	event[56]	new[56]	_	_
10-7	1278-1280	is	_	_	_	_
10-8	1281-1284	now	_	_	_	_
10-9	1285-1295	considered	_	_	_	_
10-10	1296-1298	as	_	_	_	_
10-11	1299-1306	another	abstract[57]	new[57]	_	_
10-12	1307-1314	crucial	abstract[57]	new[57]	_	_
10-13	1315-1330	pro-atherogenic	abstract[57]	new[57]	_	_
10-14	1331-1340	mechanism	abstract[57]	new[57]	_	_
10-15	1341-1345	that	abstract[57]	new[57]	_	_
10-16	1346-1349	can	abstract[57]	new[57]	_	_
10-17	1350-1354	even	abstract[57]	new[57]	_	_
10-18	1355-1362	precede	abstract[57]	new[57]	_	_
10-19	1363-1368	lipid	abstract[57]|event[58]	new[57]|new[58]	_	_
10-20	1369-1374	entry	abstract[57]|event[58]	new[57]|new[58]	_	_
10-21	1375-1379	into	abstract[57]	new[57]	_	_
10-22	1380-1383	the	abstract[57]|abstract[59]	new[57]|new[59]	ana	11-1[0_59]
10-23	1384-1392	arterial	abstract[57]|abstract[59]	new[57]|new[59]	_	_
10-24	1393-1399	intima	abstract[57]|abstract[59]	new[57]|new[59]	_	_
10-25	1400-1401	.	_	_	_	_

#Text=It has been proposed that disturbances of hemodynamic forces that are especially likely to occur at atheroprone sites of blood vessels , such as bends or bifurcations , can cause local activation of endothelial cells ( ECs ) .
11-1	1402-1404	It	abstract	giv	_	_
11-2	1405-1408	has	_	_	_	_
11-3	1409-1413	been	_	_	_	_
11-4	1414-1422	proposed	_	_	_	_
11-5	1423-1427	that	_	_	_	_
11-6	1428-1440	disturbances	event[61]	new[61]	_	_
11-7	1441-1443	of	event[61]	new[61]	_	_
11-8	1444-1455	hemodynamic	event[61]|abstract[62]	new[61]|new[62]	_	_
11-9	1456-1462	forces	event[61]|abstract[62]	new[61]|new[62]	_	_
11-10	1463-1467	that	event[61]|abstract[62]	new[61]|new[62]	_	_
11-11	1468-1471	are	event[61]|abstract[62]	new[61]|new[62]	_	_
11-12	1472-1482	especially	event[61]|abstract[62]	new[61]|new[62]	_	_
11-13	1483-1489	likely	event[61]|abstract[62]	new[61]|new[62]	_	_
11-14	1490-1492	to	event[61]|abstract[62]	new[61]|new[62]	_	_
11-15	1493-1498	occur	event[61]|abstract[62]	new[61]|new[62]	_	_
11-16	1499-1501	at	_	_	_	_
11-17	1502-1513	atheroprone	object|place[64]	new|new[64]	_	_
11-18	1514-1519	sites	place[64]	new[64]	_	_
11-19	1520-1522	of	place[64]	new[64]	_	_
11-20	1523-1528	blood	place[64]|substance|object[66]	new[64]|new|new[66]	_	_
11-21	1529-1536	vessels	place[64]|object[66]	new[64]|new[66]	_	_
11-22	1537-1538	,	place[64]	new[64]	_	_
11-23	1539-1543	such	place[64]	new[64]	_	_
11-24	1544-1546	as	place[64]	new[64]	_	_
11-25	1547-1552	bends	place[64]|object	new[64]|new	_	_
11-26	1553-1555	or	place[64]	new[64]	_	_
11-27	1556-1568	bifurcations	place[64]|abstract	new[64]|new	_	_
11-28	1569-1570	,	_	_	_	_
11-29	1571-1574	can	_	_	_	_
11-30	1575-1580	cause	_	_	_	_
11-31	1581-1586	local	event[69]	new[69]	_	_
11-32	1587-1597	activation	event[69]	new[69]	_	_
11-33	1598-1600	of	event[69]	new[69]	_	_
11-34	1601-1612	endothelial	event[69]|object|place[71]	new[69]|new|new[71]	coref	14-16[108_71]
11-35	1613-1618	cells	event[69]|place[71]	new[69]|new[71]	_	_
11-36	1619-1620	(	_	_	_	_
11-37	1621-1624	ECs	organization	new	coref	12-3
11-38	1625-1626	)	_	_	_	_
11-39	1627-1628	.	_	_	_	_

#Text=Consequently , ECs acquire a pro-inflammatory phenotype and start expressing different pro-inflammatory molecules , such as monocyte chemotactic protein 1 ( MCP1 ) ( also known as chemokine ( C-C motif ) ligand 2 ; CCL2 ) , intercellular adhesion molecule 1 ( ICAM-1 ) and vascular cell adhesion molecule 1 ( VCAM-1 ) , all of which attract monocytes to the activated endothelium .
12-1	1629-1641	Consequently	_	_	_	_
12-2	1642-1643	,	_	_	_	_
12-3	1644-1647	ECs	organization	giv	_	_
12-4	1648-1655	acquire	_	_	_	_
12-5	1656-1657	a	abstract[74]	new[74]	coref	13-7[97_74]
12-6	1658-1674	pro-inflammatory	abstract[74]	new[74]	_	_
12-7	1675-1684	phenotype	abstract[74]	new[74]	_	_
12-8	1685-1688	and	_	_	_	_
12-9	1689-1694	start	_	_	_	_
12-10	1695-1705	expressing	_	_	_	_
12-11	1706-1715	different	abstract[75]	new[75]	_	_
12-12	1716-1732	pro-inflammatory	abstract[75]	new[75]	_	_
12-13	1733-1742	molecules	abstract[75]	new[75]	_	_
12-14	1743-1744	,	abstract[75]	new[75]	_	_
12-15	1745-1749	such	abstract[75]	new[75]	_	_
12-16	1750-1752	as	abstract[75]	new[75]	_	_
12-17	1753-1761	monocyte	abstract[75]|object|substance[78]	new[75]|new|new[78]	_	_
12-18	1762-1773	chemotactic	abstract[75]|abstract|substance[78]	new[75]|new|new[78]	_	_
12-19	1774-1781	protein	abstract[75]|substance[78]	new[75]|new[78]	_	_
12-20	1782-1783	1	abstract[75]|substance[78]	new[75]|new[78]	_	_
12-21	1784-1785	(	_	_	_	_
12-22	1786-1790	MCP1	abstract	new	_	_
12-23	1791-1792	)	_	_	_	_
12-24	1793-1794	(	_	_	_	_
12-25	1795-1799	also	_	_	_	_
12-26	1800-1805	known	_	_	_	_
12-27	1806-1808	as	_	_	_	_
12-28	1809-1818	chemokine	abstract|abstract[83]	new|new[83]	appos	12-36[0_83]
12-29	1819-1820	(	abstract[83]	new[83]	_	_
12-30	1821-1824	C-C	abstract|abstract[82]|abstract[83]	new|new[82]|new[83]	_	_
12-31	1825-1830	motif	abstract[82]|abstract[83]	new[82]|new[83]	_	_
12-32	1831-1832	)	abstract[83]	new[83]	_	_
12-33	1833-1839	ligand	abstract[83]	new[83]	_	_
12-34	1840-1841	2	abstract[83]	new[83]	_	_
12-35	1842-1843	;	_	_	_	_
12-36	1844-1848	CCL2	abstract	giv	_	_
12-37	1849-1850	)	_	_	_	_
12-38	1851-1852	,	_	_	_	_
12-39	1853-1866	intercellular	abstract[86]	new[86]	appos	12-44[0_86]
12-40	1867-1875	adhesion	substance|abstract[86]	new|new[86]	coref	12-49
12-41	1876-1884	molecule	abstract[86]	new[86]	_	_
12-42	1885-1886	1	abstract[86]	new[86]	_	_
12-43	1887-1888	(	_	_	_	_
12-44	1889-1895	ICAM-1	abstract	giv	_	_
12-45	1896-1897	)	_	_	_	_
12-46	1898-1901	and	_	_	_	_
12-47	1902-1910	vascular	place[88]|abstract[90]	new[88]|new[90]	appos	12-53[0_90]
12-48	1911-1915	cell	place[88]|abstract[90]	new[88]|new[90]	_	_
12-49	1916-1924	adhesion	substance|abstract[90]	giv|new[90]	_	_
12-50	1925-1933	molecule	abstract[90]	new[90]	_	_
12-51	1934-1935	1	abstract[90]	new[90]	_	_
12-52	1936-1937	(	_	_	_	_
12-53	1938-1944	VCAM-1	abstract	giv	_	_
12-54	1945-1946	)	_	_	_	_
12-55	1947-1948	,	_	_	_	_
12-56	1949-1952	all	_	_	_	_
12-57	1953-1955	of	_	_	_	_
12-58	1956-1961	which	_	_	_	_
12-59	1962-1969	attract	_	_	_	_
12-60	1970-1979	monocytes	animal	new	_	_
12-61	1980-1982	to	_	_	_	_
12-62	1983-1986	the	animal[93]	new[93]	_	_
12-63	1987-1996	activated	animal[93]	new[93]	_	_
12-64	1997-2008	endothelium	animal[93]	new[93]	_	_
12-65	2009-2010	.	_	_	_	_

#Text=The imbalance of monocyte/macrophage polarization towards the preferential pro-inflammatory phenotype and a lack of normal inflammation resolution are also present in atherosclerosis .
13-1	2011-2014	The	abstract[94]	new[94]	_	_
13-2	2015-2024	imbalance	abstract[94]	new[94]	_	_
13-3	2025-2027	of	abstract[94]	new[94]	_	_
13-4	2028-2047	monocyte/macrophage	abstract[94]|abstract|abstract[96]	new[94]|new|new[96]	_	_
13-5	2048-2060	polarization	abstract[94]|abstract[96]	new[94]|new[96]	_	_
13-6	2061-2068	towards	abstract[94]	new[94]	_	_
13-7	2069-2072	the	abstract[94]|abstract[97]	new[94]|giv[97]	_	_
13-8	2073-2085	preferential	abstract[94]|abstract[97]	new[94]|giv[97]	_	_
13-9	2086-2102	pro-inflammatory	abstract[94]|abstract[97]	new[94]|giv[97]	_	_
13-10	2103-2112	phenotype	abstract[94]|abstract[97]	new[94]|giv[97]	_	_
13-11	2113-2116	and	_	_	_	_
13-12	2117-2118	a	abstract[98]	new[98]	_	_
13-13	2119-2123	lack	abstract[98]	new[98]	_	_
13-14	2124-2126	of	abstract[98]	new[98]	_	_
13-15	2127-2133	normal	abstract[98]|abstract[100]	new[98]|new[100]	coref	16-6[118_100]
13-16	2134-2146	inflammation	abstract[98]|event|abstract[100]	new[98]|giv|new[100]	_	_
13-17	2147-2157	resolution	abstract[98]|abstract[100]	new[98]|new[100]	_	_
13-18	2158-2161	are	_	_	_	_
13-19	2162-2166	also	_	_	_	_
13-20	2167-2174	present	_	_	_	_
13-21	2175-2177	in	_	_	_	_
13-22	2178-2193	atherosclerosis	abstract	giv	coref	18-11
13-23	2194-2195	.	_	_	_	_

#Text=Phagocytic macrophages actively participate in lipid accumulation by engulfing lipid droplets and give rise to foam cells .
14-1	2196-2206	Phagocytic	animal[102]	new[102]	_	_
14-2	2207-2218	macrophages	animal[102]	new[102]	_	_
14-3	2219-2227	actively	_	_	_	_
14-4	2228-2239	participate	_	_	_	_
14-5	2240-2242	in	_	_	_	_
14-6	2243-2248	lipid	abstract[103]	new[103]	_	_
14-7	2249-2261	accumulation	abstract[103]	new[103]	_	_
14-8	2262-2264	by	_	_	_	_
14-9	2265-2274	engulfing	_	_	_	_
14-10	2275-2280	lipid	person|substance[105]	new|new[105]	_	_
14-11	2281-2289	droplets	substance[105]	new[105]	_	_
14-12	2290-2293	and	_	_	_	_
14-13	2294-2298	give	_	_	_	_
14-14	2299-2303	rise	event	new	_	_
14-15	2304-2306	to	_	_	_	_
14-16	2307-2311	foam	substance|place[108]	new|giv[108]	coref	15-1[109_108]
14-17	2312-2317	cells	place[108]	giv[108]	_	_
14-18	2318-2319	.	_	_	_	_

#Text=Dendritic cells ( DCs ) contribute to the local inflammatory response through antigen presentation and cytokine signaling processes .
15-1	2320-2329	Dendritic	place[109]	giv[109]	appos	15-4[0_109]
15-2	2330-2335	cells	place[109]	giv[109]	_	_
15-3	2336-2337	(	_	_	_	_
15-4	2338-2341	DCs	place	giv	coref	18-6[128_0]
15-5	2342-2343	)	_	_	_	_
15-6	2344-2354	contribute	_	_	_	_
15-7	2355-2357	to	_	_	_	_
15-8	2358-2361	the	abstract[111]	new[111]	coref	17-6[123_111]
15-9	2362-2367	local	abstract[111]	new[111]	_	_
15-10	2368-2380	inflammatory	abstract[111]	new[111]	_	_
15-11	2381-2389	response	abstract[111]	new[111]	_	_
15-12	2390-2397	through	_	_	_	_
15-13	2398-2405	antigen	substance|event[113]	new|new[113]	_	_
15-14	2406-2418	presentation	event[113]	new[113]	_	_
15-15	2419-2422	and	_	_	_	_
15-16	2423-2431	cytokine	abstract|abstract[115]|abstract[116]	new|new[115]|new[116]	coref	16-9[120_116]
15-17	2432-2441	signaling	abstract[115]|abstract[116]	new[115]|new[116]	_	_
15-18	2442-2451	processes	abstract[116]	new[116]	_	_
15-19	2452-2453	.	_	_	_	_

#Text=If the inflammatory process reaches a resolution , repair processes begin , and the plaque can become stable .
16-1	2454-2456	If	_	_	_	_
16-2	2457-2460	the	event[117]	new[117]	_	_
16-3	2461-2473	inflammatory	event[117]	new[117]	_	_
16-4	2474-2481	process	event[117]	new[117]	_	_
16-5	2482-2489	reaches	_	_	_	_
16-6	2490-2491	a	abstract[118]	giv[118]	_	_
16-7	2492-2502	resolution	abstract[118]	giv[118]	_	_
16-8	2503-2504	,	_	_	_	_
16-9	2505-2511	repair	abstract|abstract[120]	new|giv[120]	_	_
16-10	2512-2521	processes	abstract[120]	giv[120]	_	_
16-11	2522-2527	begin	_	_	_	_
16-12	2528-2529	,	_	_	_	_
16-13	2530-2533	and	_	_	_	_
16-14	2534-2537	the	object[121]	giv[121]	coref	17-15[125_121]
16-15	2538-2544	plaque	object[121]	giv[121]	_	_
16-16	2545-2548	can	_	_	_	_
16-17	2549-2555	become	_	_	_	_
16-18	2556-2562	stable	_	_	_	_
16-19	2563-2564	.	_	_	_	_

#Text=However , failure to resolve the inflammatory response can result in the formation of the most dangerous unstable plaque that can cause thrombosis .
17-1	2565-2572	However	_	_	_	_
17-2	2573-2574	,	_	_	_	_
17-3	2575-2582	failure	event[122]	new[122]	_	_
17-4	2583-2585	to	event[122]	new[122]	_	_
17-5	2586-2593	resolve	event[122]	new[122]	_	_
17-6	2594-2597	the	event[122]|abstract[123]	new[122]|giv[123]	_	_
17-7	2598-2610	inflammatory	event[122]|abstract[123]	new[122]|giv[123]	_	_
17-8	2611-2619	response	event[122]|abstract[123]	new[122]|giv[123]	_	_
17-9	2620-2623	can	_	_	_	_
17-10	2624-2630	result	_	_	_	_
17-11	2631-2633	in	_	_	_	_
17-12	2634-2637	the	event[124]	new[124]	_	_
17-13	2638-2647	formation	event[124]	new[124]	_	_
17-14	2648-2650	of	event[124]	new[124]	_	_
17-15	2651-2654	the	event[124]|object[125]	new[124]|giv[125]	_	_
17-16	2655-2659	most	event[124]|object[125]	new[124]|giv[125]	_	_
17-17	2660-2669	dangerous	event[124]|object[125]	new[124]|giv[125]	_	_
17-18	2670-2678	unstable	event[124]|object[125]	new[124]|giv[125]	_	_
17-19	2679-2685	plaque	event[124]|object[125]	new[124]|giv[125]	_	_
17-20	2686-2690	that	event[124]|object[125]	new[124]|giv[125]	_	_
17-21	2691-2694	can	event[124]|object[125]	new[124]|giv[125]	_	_
17-22	2695-2700	cause	event[124]|object[125]	new[124]|giv[125]	_	_
17-23	2701-2711	thrombosis	event[124]|object[125]|abstract	new[124]|giv[125]|new	_	_
17-24	2712-2713	.	_	_	_	_

#Text=Therefore , a variety of immune cells are involved in atherosclerosis initiation and progression .
18-1	2714-2723	Therefore	_	_	_	_
18-2	2724-2725	,	_	_	_	_
18-3	2726-2727	a	abstract[127]	new[127]	_	_
18-4	2728-2735	variety	abstract[127]	new[127]	_	_
18-5	2736-2738	of	abstract[127]	new[127]	_	_
18-6	2739-2745	immune	abstract[127]|place[128]	new[127]|giv[128]	coref	19-10[135_128]
18-7	2746-2751	cells	abstract[127]|place[128]	new[127]|giv[128]	_	_
18-8	2752-2755	are	_	_	_	_
18-9	2756-2764	involved	_	_	_	_
18-10	2765-2767	in	_	_	_	_
18-11	2768-2783	atherosclerosis	abstract|event[130]	giv|new[130]	_	_
18-12	2784-2794	initiation	event[130]	new[130]	_	_
18-13	2795-2798	and	_	_	_	_
18-14	2799-2810	progression	event	giv	_	_
18-15	2811-2812	.	_	_	_	_

#Text=In this review , we consider main subsets of pro- and anti-inflammatory immune cells of myeloid origin that contribute to atherogenesis .
19-1	2813-2815	In	_	_	_	_
19-2	2816-2820	this	abstract[132]	new[132]	_	_
19-3	2821-2827	review	abstract[132]	new[132]	_	_
19-4	2828-2829	,	_	_	_	_
19-5	2830-2832	we	person	acc	_	_
19-6	2833-2841	consider	_	_	_	_
19-7	2842-2846	main	abstract[134]	new[134]	_	_
19-8	2847-2854	subsets	abstract[134]	new[134]	_	_
19-9	2855-2857	of	abstract[134]	new[134]	_	_
19-10	2858-2862	pro-	abstract[134]|place[135]	new[134]|giv[135]	_	_
19-11	2863-2866	and	abstract[134]|place[135]	new[134]|giv[135]	_	_
19-12	2867-2884	anti-inflammatory	abstract[134]|place[135]	new[134]|giv[135]	_	_
19-13	2885-2891	immune	abstract[134]|place[135]	new[134]|giv[135]	_	_
19-14	2892-2897	cells	abstract[134]|place[135]	new[134]|giv[135]	_	_
19-15	2898-2900	of	abstract[134]|place[135]	new[134]|giv[135]	_	_
19-16	2901-2908	myeloid	abstract[134]|place[135]|person|abstract[137]	new[134]|giv[135]|new|new[137]	_	_
19-17	2909-2915	origin	abstract[134]|place[135]|abstract[137]	new[134]|giv[135]|new[137]	_	_
19-18	2916-2920	that	abstract[134]|place[135]	new[134]|giv[135]	_	_
19-19	2921-2931	contribute	abstract[134]|place[135]	new[134]|giv[135]	_	_
19-20	2932-2934	to	abstract[134]|place[135]	new[134]|giv[135]	_	_
19-21	2935-2948	atherogenesis	abstract[134]|place[135]|abstract	new[134]|giv[135]|new	_	_
19-22	2949-2950	.	_	_	_	_
